Literature DB >> 11438891

Impact of a hospital-based antimicrobial management program on clinical and economic outcomes.

R Gross1, A S Morgan, D E Kinky, M Weiner, G A Gibson, N O Fishman.   

Abstract

Inappropriate use of antimicrobial agents results in unnecessary exposure to medication, persistent or progressive infection, emergence of resistance, and increased costs. We implemented a program to control use of restricted agents while improving care. This study compared 2 major mechanisms for improving use of antimicrobial agents: (1) recommendations made by the Antimicrobial Management Team (AMT), which included a clinical pharmacist backed up by a physician from the Division of Infectious Diseases (ID), and (2) recommendations made by ID fellows. Outcome measures included appropriateness of recommendations, cure rate, number of treatment failures, and cost of care, which were assessed for 180 patients. The AMT outperformed the ID fellows in all outcomes examined by the study (including appropriateness [87% vs. 47%; P<.001], cure rate [64% vs. 42%; P=.007], and treatment failures [15% vs. 28%; P=.03]), although the differences in economic outcomes between cases managed by the AMT and those managed by the ID fellows were not statistically significant. In an academic setting with a restricted formulary, the AMT demonstrated better antimicrobial prescribing than ID fellows.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438891     DOI: 10.1086/321880

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  43 in total

1.  Antimicrobial stewardship.

Authors:  Shira Doron; Lisa E Davidson
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

2.  Impact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study.

Authors:  Lucas Magedanz; Erci Maria Silliprandi; Rodrigo Pires dos Santos
Journal:  Int J Clin Pharm       Date:  2012-03-01

Review 3.  Antimicrobial stewardship programs in health care systems.

Authors:  Conan MacDougall; Ron E Polk
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

4.  Implementation of a Hemostatic and Antithrombotic Stewardship program.

Authors:  David P Reardon; Julie K Atay; Stanley W Ashley; William W Churchill; Nancy Berliner; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

Review 5.  Optimization of antibiotic use in hospitals--antimicrobial stewardship and the EU project ABS international.

Authors:  Franz Allerberger; Arno Lechner; Agnes Wechsler-Fördös; Roland Gareis
Journal:  Chemotherapy       Date:  2008-07-31       Impact factor: 2.544

Review 6.  Antibiotic stewardship through the EU project "ABS International".

Authors:  Franz Allerberger; Annegret Frank; Roland Gareis
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 7.  Point-of-prescription interventions to improve antimicrobial stewardship.

Authors:  Keith W Hamilton; Jeffrey S Gerber; Rebekah Moehring; Deverick J Anderson; Michael S Calderwood; Jennifer H Han; Jimish M Mehta; Lori A Pollack; Theoklis Zaoutis; Arjun Srinivasan; Bernard C Camins; David N Schwartz; Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2015-01-16       Impact factor: 9.079

8.  Effect of communication errors during calls to an antimicrobial stewardship program.

Authors:  Darren R Linkin; Neil O Fishman; J Richard Landis; Todd D Barton; Steven Gluckman; Jay Kostman; Joshua P Metlay
Journal:  Infect Control Hosp Epidemiol       Date:  2007-11-01       Impact factor: 3.254

9.  Prospective assessment of fluoroquinolone use in a teaching hospital.

Authors:  M Méan; P Pavese; J P Vittoz; L Foroni; C Decouchon; J P Stahl; P François
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

Review 10.  Pro/con debate: Should antimicrobial stewardship programs be adopted universally in the intensive care unit?

Authors:  Philip George; Andrew M Morris
Journal:  Crit Care       Date:  2010-02-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.